Imatinib for Melanomas Harboring Mutationally Activated or Amplified <i>KIT</i> Arising on Mucosal, Acral, and Chronically Sun-Damaged SkinF. Stephen Hodi, David E. Fisher, Christopher L. Corless et al.|Journal of Clinical Oncology|2013Cited by 594
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor FailureTimothy P. Hughes, Dong‐Wook Kim, Michael J. Mauro et al.|New England Journal of Medicine|2019Cited by 464
KIT Mutations Are Common in Incidental Gastrointestinal Stromal Tumors One Centimeter or Less in SizeChristopher L. Corless, Michael C. Heinrich|American Journal Of Pathology|2002Cited by 444
Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): Early results of RTOG 0132/ACRIN 6665Burton Eisenberg, Margaret von Mehren, Jonathan Harris et al.|Journal of Surgical Oncology|2008Cited by 419
Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trialJean‐Yves Blay, Margaret von Mehren, César Serrano et al.|The Lancet Oncology|2020Cited by 406